Fig. 3
From: Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size
a Whole blood pharmacokinetics (%ID/g blood) of [125I]mAb3D6-scFv8D3 (red) and [125I]di-scFv3D6-8D3 (blue) and a two phase decay model fitted to the data b Average brain-to-blood ratio for [125I]mAb3D6-scFv8D3 and [125I]di-scFv3D6-8D3 injected animals between 2 and 24 h c Brain pharmacokinetics of [125I]mAb3D6-scFv8D3 and [125I]di-scFv3D6-8D3 expressed as: %Injected dose per gram brain (%ID/g brain). The line represents the plateau followed by one phase decay model used to estimate the brain half-lives of [125I]mAb3D6-scFv8D3 and [125I]di-scFv3D6-8D3 d Brain pharmacokinetics of [125I]mAb3D6-scFv8D3 and [125I]di-scFv3D6-8D3 expressed as %ID/g brain normalised to body weight (bw) (%ID/g/bw), the line represents a plateau followed by one phase decay model. Values in a–d are reported as mean ± standard deviation. e–f Sagittal brain sections of three representative individuals per time point, euthanized 2, 4, 6, 8, 10, 12, 16 or 24 h after administration of [125I]mAb3D6-scFv8D3 or [125I]di-scFv3D6-8D3 g Correlation between mean intensity of ROIs in the autoradiography and the whole brain radioactivity concentration (%ID/g brain from c) for all individuals administered with [125I]mAb3D6-scFv8D3 (red, R2 = 0.74, Pearsons r = 0.86 ****p < 0.0001) or [125I]di-scFv3D6-8D3 (blue, R2 = 0.74, Pearsons r = 0.86 **** p < 0.0001)